07:00 , Sep 12, 2016 |  BC Week In Review  |  Clinical News

ARRY-371797: Phase II data

An open-label, U.S. Phase II trial in 9 evaluable patients with symptomatic dilated cardiomyopathy due to an LMNA gene mutation showed that twice-daily oral ARRY-797 improved mean 6MWT distance from baseline to 12 weeks by...
07:00 , May 12, 2014 |  BC Week In Review  |  Clinical News

ARRY-371797: Phase II started

Array began an open-label, U.S. Phase II trial to evaluate 2 dose levels of oral ARRY-797 for 48 weeks in about 12 patients with symptomatic DCM due to an LMNA gene mutation. ARRY-797 has also...